Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
Pfizer reported Q3 2026 revenue of $16.6 billion, roughly flat year-over-year, with Adjusted diluted EPS of $0.87 (flat YoY) and GAAP diluted EPS of $0.56. Underlying performance was strong outside COVID: excluding Comirnaty and Paxlovid, revenues grew 7% operationally, and launched and acquired products grew 32%, led by Eliquis (+25%), Padcev (+55%), and Lorbrena (+43%). Pfizer raised FY26 revenue guidance by $1.5 billion at the midpoint to $62.0-$64.0 billion and lifted Adjusted diluted EPS guidance to $2.95-$3.05, citing strong year-to-date performance and cost improvement initiatives.
Key figures
- Eps
- 0.87
- Revenue
- $16.6 billion
- Guidance
- FY26 revenue raised $1.5B at midpoint to $62.0-$64.0B (from $60.5-$62.5B); Adjusted diluted EPS raised and narrowed to $2.95-$3.05 (from $2.80-$3.00)
- Revenue Yoy
- flat
- Adjusted income q3
- 4985000000
- Nine month revenue
- $46,067 million
- Reported diluted eps
- 0.56
- Dividends nine months
- $7.3 billion
- Reported net income q3
- 3242000000
- Non covid operational growth
- 7%
- Acquired iprd charge innovent
- $650 million
- Remaining buyback authorization
- $3.3 billion
- Launched acquired products growth
- 32%
- Comirnaty paxlovid excluded growth
- 7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.